Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 12, Issue 5, 2013, Pages 482-486

  Waters, Valerie ^a   Atenafu, Eshetu G ^b   Lu, Annie ^a   Yau, Yvonne ^a   Tullis, Elizabeth ^c   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cystic fibrosis; Lung transplantation; Mortality; Stenotrophomonas maltophilia

Indexed keywords

ANTIBIOTIC AGENT; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS; BACTERIAL INFECTION; BACTERIAL STRAIN; BODY MASS; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA CEPACIA INFECTION; CANADA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HAZARD RATIO; HOSPITAL; HUMAN; LONGITUDINAL STUDY; LUNG ASPERGILLOSIS; LUNG CYSTIC FIBROSIS; LUNG DISEASE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PANCREAS; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA INFECTION; SURGICAL PATIENT;

CYSTIC FIBROSIS; LUNG TRANSPLANTATION; MORTALITY; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COHORT STUDIES; CYSTIC FIBROSIS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LONGITUDINAL STUDIES; LUNG TRANSPLANTATION; MALE; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT;

EID: 84882928602     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.12.006     Document Type: Article

References (22)

1. Waters V., Yau Y., Prasad S., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011, 183(5):635-640.
2. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153(4):345-352.
3. Goss C.H., Mayer-Hamblett N., Aitken M.L., Rubenfeld G.D., Ramsey B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59(11):955-959.
4. Goss C.H., Otto K., Aitken M.L., Rubenfeld G.D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166(3):356-361.
5. 1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178(8):814-821.
6. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303(23):2386-2392.
7. Kerem E., Reisman J., Corey M., Canny G.J., Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992, 326(18):1187-1191.
8. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168(8):918-951.
9. Cystic Fibrosis Canada Canadian Patient Data Registry Report. Toronto, Canada 2009.
10. Radhakrishnan D.K., Yau Y., Corey M., et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009, 44(11):1100-1106.
11. Corey M., Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996, 143(10):1007-1017.
12. Isles A., Maclusky I., Corey M., et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984, 104(2):206-210.
13. Jones A.M., Dodd M.E., Govan J.R., et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004, 59(11):948-951.
14. Courtney J.M., Dunbar K.E., McDowell A., et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004, 3(2):93-98.
15. Murray S., Charbeneau J., Marshall B.C., LiPuma J.J. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008, 178(4):363-371.
16. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34(2):91-100.
17. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992, 12(3):158-161.
18. Courtney J.M., Bradley J., McCaughan J., et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007, 42(6):525-532.
19. Ramsey B.W., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340(1):23-30.
20. Amin R., Waters V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev 2012, 5:CD009249.
21. Waters V. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr Pharm Des 2012, 18(5):696-725.
22. Aaron S.D., Vandemheen K.L., Ramotar K., et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010, 304(19):2145-2153.